Pharmacolog i Uppsala AB (publ) develops systems and solutions for use of intravenous drugs in Sweden. More Details
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Pharmacolog i Uppsala's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PUPP.F has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: Insufficient data to determine how PUPP.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how PUPP.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Pharmacolog i Uppsala's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Pharmacolog i Uppsala undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PUPP.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PUPP.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PUPP.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: PUPP.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PUPP.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PUPP.F is overvalued based on its PB Ratio (4.4x) compared to the US Medical Equipment industry average (4x).
How is Pharmacolog i Uppsala forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmacolog i Uppsala has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of PUPP.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Pharmacolog i Uppsala's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
How has Pharmacolog i Uppsala performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PUPP.F is currently unprofitable.
Growing Profit Margin: PUPP.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PUPP.F is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare PUPP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PUPP.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: PUPP.F has a negative Return on Equity (-131.96%), as it is currently unprofitable.
How is Pharmacolog i Uppsala's financial position?
Financial Position Analysis
Short Term Liabilities: PUPP.F's short term assets (SEK11.2M) exceed its short term liabilities (SEK2.4M).
Long Term Liabilities: PUPP.F's short term assets (SEK11.2M) exceed its long term liabilities (SEK1.1M).
Debt to Equity History and Analysis
Debt Level: PUPP.F's debt to equity ratio (10.9%) is considered satisfactory.
Reducing Debt: PUPP.F's debt to equity ratio has increased from 1% to 10.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PUPP.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PUPP.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.5% each year
What is Pharmacolog i Uppsala current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PUPP.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PUPP.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PUPP.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PUPP.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PUPP.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mats Högberg (56 yo)
Mr. Mats Högberg serves as the Chief Executive Officer of Pharmacolog i Uppsala AB (publ) and was its Director since 2017 until 2019. Mr. Högberg served as the Vice President of Sales & Marketing at Pharma ...
|Independent Director||1.67yrs||no data||no data|
|Chairman of the Board||3.5yrs||no data||no data|
|Independent Director||1.67yrs||no data||no data|
|Director||no data||no data||no data|
Experienced Board: PUPP.F's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pharmacolog i Uppsala AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Pharmacolog i Uppsala AB (publ)
- Ticker: PUPP.F
- Exchange: OTCPK
- Founded: 2007
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr49.916m
- Listing Market Cap: kr5.556m
- Shares outstanding: 9.92m
- Website: https://www.pharmacolog.com
Number of Employees
- Pharmacolog i Uppsala AB (publ)
- Ekeby bruk
- Uppsala County
- 752 75
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHLOG B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||Jun 2015|
|PUPP.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||Jun 2015|
Pharmacolog i Uppsala AB (publ) develops systems and solutions for use of intravenous drugs in Sweden. The company offers DrugLog, a solution for reducing errors in the drug administration process; WasteLo ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/29 23:40|
|End of Day Share Price||2020/08/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.